anonymous
Guest
anonymous
Guest
Livalo has been a great drug in a generic only dominant statin market. It has produced great revenue numbers. HCPs know how and where to use it and will FIGHT for it. My question is why did upper manager decide to neglect it the past year? DMs directed reps to focus only on SEG basically. Fill all the pharmacies (when it wasn’t possible), chase reversals, cancel all Livalo lunches and seeing your Livalo doctors less. Even the marketing team stopped producing new materials in 2021.
Will the past year revenue numbers for Livalo be lower than record years? Or has upper management missed out on another record Livalo year because they directed reps to not really focus on it at all. It may impact the last year sales of Livalo by hundreds of millions? Just a thought.
Bystolic had more attention it’s last year and sales increased even before it went generic!
Who make the decision to ignore Livalo prescribers the past year?
Will the past year revenue numbers for Livalo be lower than record years? Or has upper management missed out on another record Livalo year because they directed reps to not really focus on it at all. It may impact the last year sales of Livalo by hundreds of millions? Just a thought.
Bystolic had more attention it’s last year and sales increased even before it went generic!
Who make the decision to ignore Livalo prescribers the past year?